(Q38169313)

English

Drug discovery considerations in the development of covalent inhibitors

scientific article published on 10 October 2013

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

30 August 2017

Drug discovery considerations in the development of covalent inhibitors (English)

1 reference

stated in

Europe PubMed Central

30 August 2017

1 reference

Robert Mah

1

1 reference

stated in

Europe PubMed Central

PubMed ID

24314671

retrieved

30 August 2017

Jason R Thomas

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed ID

24314671

retrieved

30 August 2017

Cynthia M Shafer

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed ID

24314671

retrieved

30 August 2017

language of work or name

English

0 references

publication date

10 October 2013

1 reference

stated in

Europe PubMed Central

30 August 2017

Bioorganic & Medicinal Chemistry Letters

1 reference

stated in

Europe PubMed Central

30 August 2017

24

1 reference

stated in

Europe PubMed Central

30 August 2017

1

1 reference

stated in

Europe PubMed Central

30 August 2017

33-39

1 reference

stated in

Europe PubMed Central

30 August 2017

From mechanism to mouse: a tale of two bioorthogonal reactions

1 reference

5 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1021/AR200148Z

Identifiers

DOI

10.1016/J.BMCL.2013.10.003

1 reference

stated in

Europe PubMed Central

30 August 2017

1 reference

Europe PubMed Central

PubMed ID

24314671

retrieved

30 August 2017

ResearchGate publication ID

259245139

0 references

(Q38169313)

Drug discovery considerations in the development of covalent inhibitors

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)